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Abstract
Background: Several candidate genes on the short arm of chromosome 6 including the HLA locus, TNF, LTA and AGER could
be associated with late diabetic complications. The aim of our study was therefore to explore whether polymorphisms (TNF -
308 GRA, LTA T60N CRA and AGER -374 TRA) in these genes alone or together (as haplotypes) increased the risk for
diabetic complications.
Methodology/Principal Findings: The studied polymorphisms were genotyped in 742 type 1 and 2957 type 2 diabetic
patients as well as in 206 non-diabetic control subjects. The Haploview program was used to analyze putative linkage
disequilibrium between studied polymorphisms. The TNF, LTA and AGER polymorphisms were associated with the HLA-
DQB1 risk genotypes. The AGER -374 A allele was more common in type 1 diabetic patients with than without diabetic
nephropathy (31.2 vs. 28.4%, p=0.007). In a logistic regression analysis, the LTA but not the AGER polymorphism was
associated with diabetic nephropathy (OR 2.55[1.11–5.86], p=0.03). The AGER -374 A allele was associated with increased
risk of sight threatening retinopathy in type 2 diabetic patients (1.65[1.11–2.45], p=0.01) and also with increased risk for
macrovascular disease in type 1 diabetic patients (OR 2.05[1.19–3.54], p=0.01), but with decreased risk for macrovascular
disease in type 2 diabetic patients (OR 0.66[0.49–0.90], p=0.009). The TNF A allele was associated with increased risk for
macrovascular complications in type 2 (OR 1.53 [1.04–2.25], p=0.03, but not in type 1 diabetic patients.
Conclusions/Significance: The association between diabetic complications and LTA, TNF and AGER polymorphisms is
complex, with partly different alleles conferring susceptibility in type 1 and type 2 diabetic patients. We can not exclude the
possibility that the genes are part of a large haplotype block that also includes HLA-DQB1 risk genotypes.
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Introduction
The etiology of diabetic complications is complex, and
inflammation may play a role [1]. The mRNA expression for
pro-inflammatory cytokines such as IL-1 and Tumor Necrosis
Factor Alpha (TNF-a) is increased in the retina and animal studies
suggest that inhibition of TNF-a has beneficial effects in
prevention of diabetic retinopathy [2,3]. Recently, we have shown
that type 1 diabetic patients with proliferative retinopathy have
increased levels of TNF- a [4]. Similarly, inflammatory markers
are elevated in diabetic nephropathy [5] and inflammation is
associated with development of macrovascular complications such
as myocardial infarction [6]. TNF-a and lymphotoxin-a (LT-a,
also known as TNF-b) belong to the same TNF family and are
encoded by the same gene cluster. TNF-a is mainly produced by
activated macrophages and LT-a by T, B and natural killer cell
lymphocytes [7]. Promoter variants -308ARG and -238GRAi n
the gene coding for TNF-a (TNF) affect transcriptional regulation
of the gene coding for LT-a (LTA) [8]. The receptor for advanced
glycation end products (RAGE) is also mainly considered as an
intracellular signal and transducer or proinflammatory peptide [9].
LTA, TNF and the gene encoding for RAGE (AGER) are all
located within the MHC complex on the short arm of chromosome
6. The HLA locus is among the most polymorphic in the human
genome. Some studies have suggested a direct role of HLA in
development of diabetic nephropathy [10], retinopathy [11] and
macrovascular disease [12]. Sincethis region alsoharbours a variety
ofothergenesinvolvedininflammation,the resultscouldalsoreflect
variationinothergenesthan HLA.Wehaverecentlyshown AGER-
374TRA polymorphism to be associated with diabetic nephropa-
thy and possibly with retinopathy in type 1, but not in type 2
diabetic patients [13]. The results concerning the risk allele (A) in
the AGER gene were in conflict with a previous study [14], and a
possible explanation could be that the AGER gene is in linkage
disequilibrium with other genes, such as TNF and LTA.
Variation in TNF and LTA genes has been associated with
diabetic nephropathy [15], retinopathy [16] as well as with
cardiovascular and cerebrovascular disease [17,18]. A large
genome-scan in Japanese patients identified a susceptibility locus
for myocardial infarction on chromosome 6p21 [19], especially the
256ARG and T60N (also referred to as T26N in some studies)
variants in the LTA gene, were associated with myocardial
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neither confirm the association with myocardial infarction, nor the
association with inflammatory biomarkers [20].
The TNF/LTA locus is in linkage disequilibrium with HLA-
DQB1 [21] and we have previously shown that the AGER -
374TRA polymorphism is associated with the HLA-DQB1 risk
genotypes [13]. In a recent study the HLA 8.1 ancestral haplotype
was shown to be strongly linked to the C allele of the AGER -
429TRC promoter polymorphism [22]. Our aim was to study
whether variants in these genes form a putative haplotype
associated with increased risk of diabetic nephropathy, retinopathy
and macrovascular disease.
Results
Type 2 diabetic patients were older and had higher BMI than
type 1 diabetic patients or non-diabetic controls (Table 1).
Genotype distributions of LTA, TNF and AGER polymorphisms
are shown in Table 2. All three variants deviated from the Hardy–
Weinberg equilibrium in type 1, but neither in type 2 diabetic
patients nor in non-diabetic controls. In type 1 diabetic patients
there was an excess of heterozygous patients with LTA (p,0.0002),
TNF (p=0.02) and AGER (p=0.008). The genotype frequencies of
the LTA, TNF and AGER polymorphisms were different between
type 1 diabetic patients and controls and also between type 1 and
type 2 diabetic patients. The LTA, TNF and AGER polymorphisms
were associated with the HLA-DQB1 genotypes (Table 3). The
minor allele (A) of the LTA polymorphism was less common in
patients with than without HLA-DQB1 genotypes risk genotypes
(37.2 vs. 43.9%, p=0.0001). No difference in allele frequencies of
the TNF polymorphism was seen between patients with or without
HLA-DQB1 risk genotypes, however the minor allele (A) of the
AGER polymorphism was more common in patients with than
without HLA-DQB1 risk alleles (34.5 vs. 22.9%), p,0.000001).
Because of lack of Hardy–Weinberg equilibrium in type 1 diabetic
patients, we could not confirm whether the LTA, TNF and AGER
polymorphisms were in LD in type 1 diabetic patients. In type 2
diabetic patients and controls the LTA and TNF polymorphisms
were in LD (D9=1.00 [0.99–1.00] , r
2=0.4). The AGER
polymorphism was neither in LD with LTA (D9 0.13 [0.06–
0.20], r
2=0.004) nor with TNF (D9 0.36 [0.23–0.43], r
2=0.009)
in type 2 diabetic patients.
Diabetic Nephropathy
Type 1 diabetic patients with diabetic nephropathy had a higher
frequency of the RAGE -374 A allele (31.2%) compared to those
who maintained normoalbuminuria $10 years (28.4%) (P=0.007)
(Table 4) and the difference remained even after correction for
multiple comparisons (p=0.02). The allele frequencies of TNF -
308 GRA and LTA T60N polymorphisms were similar in type 1
diabetic patients with and without diabetic nephropathy. No
differences in allele or haplotype frequencies of the studied
polymorphisms were observed between type 2 diabetic patients
with and without diabetic nephropathy (Table 4). In a logistic
regression analysis with age, duration, BMI, HbA1c, systolic and
diastolic blood pressure, sex, previous or current smoking and
studied polymorphisms and HLA-DQB1 risk genotypes as
independent variables, having the LTA T60N A allele in type 1
diabetic patients was associated with increased risk diabetic
nephropathy (OR 2.55[1.11–5.86],p=0.03), (Figure 1a). In type
2 diabetic patients, the HLA-DQB1 risk allele but not LTA, TNF
and AGER polymorphisms was associated with increased risk for
diabetic nephropathy (1.75 [1.05–2.94], p=0.03). LTA, TNF and
AGER polymorphisms were not associated with diabetic nephrop-
athy in type 2 diabetic patients (Figure 1b).
Diabetic retinopathy
The allele (or haplotype) frequencies of the studied polymor-
phisms did not differ between patients with and without sight-
threatening retinopathy, neither in type 1 nor in type 2 diabetic
patients (Table 4). In a logistic regression analysis with age,
duration, HbA1c, systolic and diastolic blood pressure, sex,
current/previous smoking and genotypes as independent vari-
ables, HLA-DQB1 risk genotype was associated with decreased risk
for sight-threatening retinopathy in type 1 diabetic patients
(0.66[0.44–0.99], p=0.04). In contrast LTA, TNF and AGER
polymorphisms were not associated with sight-threatening reti-
nopathy in type 1 diabetic patients (Figure 1a). In type 2 diabetic
patients the AGER A allele was associated with increased risk for
sight-threatening retinopathy (1.65[1.11–2.45], p=0.01)
(Figure 1b).
Macrovascular complications
Type 1 diabetic patients with a history of macrovascular
complications had higher frequency of the LTA A allele than
patients without macrovascular complications (52.7% vs. 44.8%,
p=0.03) (Table 4). The allele frequencies of the TNF and AGER
polymorphisms did not differ between type 1 diabetic patients with
and without history of macrovascular disease.
In a logistic regression analysis, the AGER – 374 A allele was
associated with increased risk for macrovascular complications
(OR 2.05[1.19–3.54], p=0.01), Figure 1a) in type 1 diabetic
patients. The HLA-DQB1 risk genotype was associated with
decreased risk for macrovascular disease in type 1 diabetic patients
(OR 0.49[0.28–0.86], p=0.01). The gene-gene interaction was
tested in a separate logistic regression model (assuming a dominant
model) by adding a term (AGER)6(HLA risk genotype). The
gene-gene interaction term was however not significant and was
therefore not included in the final model (Figure 1a).
In type 2 diabetic patients the frequency of both TNF -308 A
allele and AGER -374 T allele genotype was higher in patients with
than without macrovascular complications (21.6% vs. 18.1%,
p=0.003 and 76.7% vs. 73.5%, p=0.03, respectively) (Table 4),
the significance of difference in frequency of AGER -374
polymorphism did not stand multiple comparisons (Table 4).
The AA haplotype of TNF and LTA was more common in type 2
diabetic patients with than without macrovascular disease (21.5%
Table 1. Clinical characteristics of the patients and non-
diabetic control subjects.
Controls Type 1 Type 2
N (M/F) 107/99 458/375 2240/1616
Age (yrs.) 59.7612.6
a 38.2613.6 61.2611.7
b
Age at diagnosis (yrs.) - 18.269.1 55.6612.2
Diabetes duration (yrs.) - 18.1[8.5–29.6] 2.58[0.09–9.54]
BMI (kg/m
2)2 5 . 8 63.8
a 23.863.1 29.765.6
a
HbA1c (%) - 7.261.3 6.661.3
Systolic BP (mmHg) - 130.6618.9 144.8621.8
Diastolic BP (mmHg) - 74.269.6 80.9610.9
Smokers (current or previous) - 51.5% 61.1%
ap,0.000001.
bp=0.01. Type 1 and type 2 diabetic patients vs. controls.
doi:10.1371/journal.pone.0002546.t001
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A allele (OR 1.53[1.04–2.25], p=0.03) was associated with
increased and the AGER -374 A allele with decreased risk (OR
0.66[0.49–0.90], p=0.009) for macrovascular disease (Figure 1b).
The gene-gene interaction was tested in a separate logistic
regression model (assuming a dominant model) by adding a term
(AGER)6(TNF). The gene-gene interaction term was however not
significant and was therefore not included in the final model
(Figure 1b).
Discussion
The key finding of the present study was that the polymor-
phisms in the TNF, LTA and AGER genes were associated with
high risk HLA-DQB1 alleles on chromosome 6p21 and that they
influenced the risk for late diabetic complications. The TNF, LTA
and AGER alleles were in Hardy-Weinberg equilibrium in as well
in non-diabetic controls as in type 2 diabetic patients. In type 1
diabetic patients all of the studied polymorphisms deviated from
Hardy-Weinberg equilibrium having excess of heterozygous
alleles. This is well in line with previous observations of a
synergistic effect of the DR3 and DR4 haplotypes DRB1*0301-
DQA1*0501-DQB1*0201 and DRB1*0401-DQA1*0301-
DQB1*0302 which are strongly associated with type 1 diabetes
thus leading to excess of heterozygous versus homozygous patients
[23]. Deviation from Hardy-Weinberg equilibrium will influence
the estimated haplotype frequencies especially in a situation with
excess of homozygous patients [24]. Therefore, we could not test
whether LTA, TNF and AGER polymorphisms are in linkage
disequilibrium in type 1 diabetic patients as suggested by Laki et.
al. who recently showed that the HLA 8.1 ancestral haplotype (8.1
AH) was strongly linked to the AGER -429TRC polymorphism
and the AGER -429 allele should therefore be considered as
candidate member of the HLA 8.1 ancestral haplotype [22].
The association patterns between diabetic complications and
polymorphisms in LTA, TNF, AGER and HLA was complex and
none of the studied polymorphism was associated with all diabetic
complications in either type 1 or type 2 diabetic patients. For
example, the A allele of the AGER -374 polymorphism was more
common in type 1 diabetic patients with than without diabetic
nephropathy. In a regression model however, when all of the
polymorphisms and HLA-DQB1 risk genotype were included in the
model, LTA rather than AGER was a risk factor for diabetic
nephropathy in type 1 diabetic patients. Similarly, the AGER A
allele was associated with increased risk for sight-threatening
retinopathy but decreased risk for macrovascular disease in type 2
diabetic patients which raises a question, whether this could
represent a survival bias because of the strong association between
TNF and AGER polymorphisms and macrovascular disease.
The lack of association in type 1 diabetic patients could of
course be due to small sample size. Another possible source of bias
could be population stratification due to ethically diverse samples,
which is not very likely given the fact that all patients were
Scandinavians. Previous studies on the putative association
between polymorphisms in the LTA, TNF and RAGE genes and
micro-and macrovascular complications in type 2 diabetes have
given conflicting results [14–20,25–30]. Differences in study
design, insufficient power and inclusion of different ethnic groups
might explain some of the observed differences, as would inclusion
of type 2 diabetic patients with LADA [30]. To circumvent this
problem we excluded adult patients who were GAD antibody
positive or required insulin therapy during the first year.
Some of the discrepancy in the published literature could also
be due to the complex pattern of LD in the region. The HLA
region on the short arm of chromosome 6 contains several genes
Table 2. Genotype frequencies (%) of LTA T60N (CRA), TNF -308 GRA and AGER -374 TRA polymorphism in nondiabetic controls
and in type 1 and type 2 diabetic patients.
Controls Type 1 p Corrected p Type 2 Corrected p
LTA T60N (CC/CA/AA) 77/88/35 (38.5/44.0/17.5) 186/409/131 (25.6/56.3/18.0) 0.0003 0.05 1089/1395/436 (37.3/47.8/14.9) 0.73 1.00
TNF -308 (GG/GA/AA) 133/66/6 (64.9/32.2/2.9) 350/329/50 (48.0/45.1/6.9) 0.00002 0.00009 1908/906/113 (65.2/31.0/3.9) 0.93 1.00
AGER -374 (TT/TA/AA) 127/67/11 (62.0/32.7/5.4) 350/335/48 (47.7/45.7/6.5) 0.0003 0.007 1624/1108/198 (55.4/37.8/6.8) 0.07 0.31
The uncorrected p-value refers to differences in genotype frequencies (CC vs CA/AA, GG vs. GA/AA and TT vs. TA/AA). Corrected p-value refers to differences in allele
frequencies after 100 000 permutations (haploview).
doi:10.1371/journal.pone.0002546.t002
Table 3. Minor allele frequencies according to HLA-DQB1
genotype in type 1 diabetic patients.
LTA (A allele)
a TNF (A allele)
b AGER (A allele)
c
02/0301 26 (59.1) 17 (38.6) 5 (11.9)
02/0302 214 (46.7) 174 (38.2) 131 (28.0)
02/0602
d 2 (100.0) 1 (50.0) 1 (50.0)
02/0603
d 6 (50.0) 5 (41.7) 2 (16.7)
02/0604 26 (68.4) 13 (34.2) 2 (5.0)
02/X 114 (67.1) 101 (58.7) 20 (11.6)
0301/0302 29 (45.3) 13 (20.3) 28 (43.8)
0301/0602
d 1 (50.0) 0 (0.0) 2 (100.0)
0301/0603
d 5 (83.3) 0 (0.0) 1 (16.7)
0301/0604
d 3 (50.0) 0 (0.0) 1 (16.7)
0301/X 9 (40.9) 0 (0.0) 9 (40.9)
0302/0602
d 1 (16.7) 0 (0.0) 3 (37.5)
0302/0603 33 (43.4) 6 (20.0) 14 (46.7)
0302/0604 33 (43.4) 4 (5.1) 20 (26.3)
0302/X 54 (22.7) 18 (7.5) 116 (48.3)
0602/03/04/X
d 8 (42.9) 12 (14.3) 11 (21.4)
0604/X 10 (50.0) 1 (5.0) 5 (25.0)
X/X 9 (45.0) 2 (10.0) 8 (40.0)
Numbers are number of alleles N (%).
aP,0.000001, Chi-Square=94.2 df=11.
bP,0.000001, Chi-Square=196.3,df=11.
cP,0.000001, Chi-Square=98.8,df=11.
dExpected value ,5 in type 1 diabetes. These genotypes were pooled in the
statistical analysis. X could mean either a homozygous allele or any allele other
than 02, 0301, 0302, 0602 or 0604.
doi:10.1371/journal.pone.0002546.t003
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PLoS ONE | www.plosone.org 3 June 2008 | Volume 3 | Issue 6 | e2546Figure 1. Logistic regression analysis in type 1 (1a) and type 2 (1b) diabetic patients with LTA T60N (CRA), TNF -308 GRA, AGER -374
TRA polymorphisms and HLA-DQB1 risk genotypes as independent and diabetic complication as dependent variable. Age, systolic
and diastolic blood pressure, sex, previous/current smoking are included in all models. BMI is included in the models for nephropathy and
macrovascular disease, duration in the models for nephropathy and retinopathy and age at diagnosis in the model for macrovascular disease.
doi:10.1371/journal.pone.0002546.g001
Table 4. Allelic association of LTA T60N (CRA), TNF -308GRA and AGER -374 TRA polymorphism with diabetic nephropathy,
retinopathy and macrovascular complications.
Type 1 Type 2
NEPHROPATHY
N p corrected p N p corrected p
LTA T60N CRA Controls 340 27.9/53.2/18.9 0.317 0.918 442 33.3/47.3/19.5 0.205 0.592
Cases 113 18.6/63.7/17.7 314 37.2/45.9/16.9
TNF -308 GRA Controls 342 47.7/46.5/5.8 0.503 0.983 438 63.9/30.4/5.7 0.559 0.970
Cases 113 44.2/48.7/7.1 314 65.0/30.9/4.1
AGER -374 TRA Controls 345 52.2/41.2/6.7 0.007 0.023 439 54.2/37.6/8.2 0.119 0.509
Cases 114 34.2/57.9/7.9 315 58.1/37.1/4.8
RETINOPATHY
LTA T60N CRA Controls 310 29.4/53.5/17.1 0.154 0.461 584 34.1/49.8/16.1 0.608 0.986
Cases 310 21.6/60.6/17.7 296 37.5/45.6/16.9
TNF -308 GRA Controls 307 50.2/43.6/6.2 0.573 0.982 583 65.0/30.7/4.3 0.368 0.878
Cases 315 46.0/48.9/5.1 295 67.8/28.8/3.4
AGER -374 TRA Controls 313 48.9/45.3/5.8 0.295 0.774 583 54.9/36.5/8.6 0.734 0.998
Cases 315 44.8/47.9/7.3 298 50.3/44.0/5.7
MACROVASCULAR COMPLICATIONS
LTA T60N CRA Controls 609 27.6/55.2/17.2 0.034 0.122 1802 38.1/47.5/14.4 0.102 0.456
Cases 112 15.2/64.3/20.5 885 35.0/48.6/16.4
TNF -308 GRA Controls 611 49.3/44.0/6.7 0.426 0.916 1804 67.3/29.2/3.5 0.003 0.017
Cases 113 42.5/52.2/5.3 886 61.4/34.1/4.5
AGER -374 TRA Controls 617 48.8/44.6/6.6 0.299 0.797 1809 54.4/38.1/7.5 0.010 0.052
Cases 111 41.4/52.3/6.3 888 58.8/35.9/5.3
The uncorrected p-value refers to differences in allele frequencies. Corrected p-value refers to differences in allele frequencies using after 100 000 permutations
(Haploview).
doi:10.1371/journal.pone.0002546.t004
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complex and there is also a complex interaction between genes
and gene products, as illustrated by the TNF gene polymorphism
that can influence transcription of LTA [8], and receptor for
advanced glycation end-products (RAGE), which after binding to
its ligand can increase production of pro-inflammatory cytokines,
among them TNF-a [31].
Taken together the data show that polymorphisms in the LTA,
TNF and AGER genes increase risk of diabetic micro- and
macroangiopathy either alone or together. Given the strong
association with HLA-risk genotypes we can not rule out that they
are part of a same haplotype and their risk on disease can therefore
only be judged from studies assessing them all.
Materials and Methods
A detailed description of study subjects and analytical methods
has been given previously [13]. The study population was mainly
the same as in the previous study. However, additional 98 type 1
and 796 type 2 diabetic patients were included and genotyped for
the AGER -374TRA polymorphism in this study and all the
patients were also genotyped for the TNF -308 GRA and LTA
T60N CRA polymorphisms. Patients were classified as having
type 1 or type 2 diabetes by the attending physician using the
World Health Organization (WHO) guidelines of 1985 [23] or,
when diagnosed after January 1, 2001, according to the new
WHO guidelines [24]. Type 1 diabetic patients with age at onset
.35 years (N=224) and type 2 diabetic patients positive for GAD
antibodies (N=197) were excluded. In addition, type 2 diabetic
patients with an age at diagnosis ,35 years and with permanent
insulin treatment during the first year from diagnosis were
excluded (N=108). A total of 3699 (742 type 1 and 2957 type 2
diabetes) Scandinavian patients and 206 Scandinavian, non-
diabetic control subjects were included in the study. Control
subjects were selected among spouses of patients with hyperten-
sion; they were not allowed to have any first degree relatives with
diabetes. No information on hypertension or myocardial infarction
in non-diabetic control subjects was available. The Ethics
committee of Malmo ¨/Lund approved the study. Informed consent
was obtained from all patients.
Assessment of complications
Diabetic nephropathy. The urinary albumin concentration
was determined by immunonephelometry (Beckman Instruments,
CA, USA) until 1998 and thereafter by an immunoturbimetric
method (Beckman Coulter, Beckman Instruments, CA, USA).
Albuminuria was reported either as mg/min (AER), mg/24 hours
or as a urinary albumin/creatinine ratio (g/mol).
Microalbuminuria was defined as 20–200 mg/min, 30–300 mg/
24 hours or 2.0–25 in males and 2.8–25 g/mol in females. For the
definition of microalbuminuria we also considered older values
given as the urinary albumin concentration measured in a first
morning specimen. Values of 30–300 mg/l were considered as
microalbuminuria. Values above the upper limit were indicative of
macroalbuminuria. Macroalbuminuria was considered present
when at least two values above the cut-off limit for
macroalbuminuria were recorded. One positive measurement
only was considered as macroalbuminuria if the patient thereafter
was treated with ACE inhibitors or angiotensin II receptor
blockers or if the patient had had persistent microalbuminuria
previously. Patients with other kidney diseases were excluded from
the analysis. Normoalbuminuria required that all urinary albumin
measurements were within the normal range, otherwise the
albuminuria status was considered unknown. Duration of
albuminuria was calculated from the onset of microalbuminuria
when known, or from the latest measurement with no
albuminuria. If not known (60% of all the cases with micro- or
macroalbuminuria, 39% in type 1 diabetic patients) the duration
was calculated from the first registered value of micro- or
macroalbuminuria. When calculating the genotype frequencies
in patients with normoalbuminuria, only patients with diabetes
duration $10 years were included.
Diabetic Retinopathy. Information about the retinopathy
status was available in 3072 patients. Patients were divided into
two groups; subjects with no or non-proliferative retinopathy
without macular edema and subjects with sight-threatening
retinopathy, which included patients with proliferative
retinopathy and/or photocoagulation treatment (panretinal and/
or focal/grid for macular edema). The duration of sight-
threatening retinopathy was defined from the first information of
diagnosis or laser treatment. When calculating the genotype
frequencies in patients without sight-threatening retinopathy only
those with diabetes duration $10 years were included.
Macrovascular disease. Macrovascular disease was defined
as previously diagnosed myocardial infarction, angina pectoris,
transitory ischemic attack (TIA), stroke and/or peripheral vascular
disease. Information on previous macrovascular disease was
available in 93% of the patients.
In logistic regression analysis age at diagnosis was used in stead
of duration because the macrovascular disease duration was often
unknown and sometimes a decade before the onset of diabetes.
Lipid levels were not used in the regression analysis, because
according to the clinical guidelines patients with previous episode
of myocardial infarction or stroke should be treated with statins.
Consequently, current cholesterol levels were lower in patients
with previous episode of macrovascular disease and we did not
have access to historical data.
Genotyping
T60N CRA (rs1041981), TNF -308 GRA (rs1800629), and
AGER -374 TRA (rs1800624) polymorphisms were genotyped
using the allelic discrimination method on the ABI 7900
instrument (Applied Biosystems, Foster City, CA). A subset of
patient (629 type 1 and 1108 type 2 diabetic patients and all
control subjects were previously genotyped for HLA-DQB1 [13].
The genotyping success rates were 99.0% for the LTA, 98.7% for
the TNF and 98.4% for the AGER polymorphisms. Re-genotyping
was performed in a separate analysis in random samples from
those which passed. A total of 226 (LTA), 234 (TNF) and 225
(AGER) patients were re-genotyped with a 100% genotyping
concordance rate.
Statistical analysis
Data are presented as mean6SD or as median and interquartile
range [25
th–75
th]. Chi-square test was used to test for frequency
differences between studied genotypes. To test differences between
group means, the Student’s two-tailed t-test was used for normally
distributed values and Mann-Whitney U-test for non-normally
distributed medians. In order to assess factors associated with
diabetic nephropathy, retinopathy and macrovascular disease, a
multiple logistic regression analysis with forward selection was
performed. All data were analysed with a NCSS 2004 (NCSS
statistical software, Kaysville, UT, USA). A p-value ,0.05 was
considered statistically significant. To evaluate putative haplotype
blocks, linkage disequilibrium (LD) between the SNPs was
analyzed using Haploview 3.32 and D9 values were calculated
with 95% confidence intervals (CI) when the genotype frequencies
were in Hardy-Weinberg equilibrium [32]. A corrected p-value
LTA, TNF and AGER in Diabetes
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haplotype blocks including the TNF, LTA and AGER polymor-
phisms. Power analysis was made using Genetic Power calculator
[33]. HW-QuickCheck software [34] was used for testing of
putative excess of heterozygous/ homozygous patients.
Power calculations. Power assuming a=0.05 and relative
risk of 1.3 was 11%, 31% and 32% for type 1 diabetic patients and
62%, 81% and 80% for type 2 diabetic patients with or without
diabetic nephropathy for the LTA, TNF and AGER
polymorphisms. The power for retinopathy was 68%, 86% and
85% in type 1 and 58%, 73% and 73% in type 2 diabetes and for
macrovascular disease 20%, 28% and 28% in type 1 and 97%,
99% and 99% in type 2 diabetes.
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